Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one‐year study

Abstract

Our study demonstrated a favorable effect on lipoprotein profiles with both hormone replacement therapy regimens. Dydrogesterone appears to be superior to medroxyprogesterone acetate from the perspective of modification of coronary heart disease risk factors.

Differential effect of the ultra‐low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women

“…To date, only a few studies have reported the effect of estrogen plus dydrogesterone (E+D) on AT. Chang et al observed AT reduction in both treatment groups with E+D and estrogen plus medroxyprogesterone (MP) after 12 months of therapy. Bonduki et al conducted two studies where they observed the decrease in AT after oral estrogen plus MP therapy.…”